Presbia PLC is a company that represents values of innovation, commitment to excellence, and patient-focused approach. With a corporate philosophy rooted in the development of advanced ophthalmic solutions, Presbia aims to provide effective treatments to enhance vision and improve the quality of life for individuals suffering from presbyopia. By delivering cutting-edge technology and investing in research and development, Presbia is dedicated to revolutionizing the field of vision correction. Through its unwavering dedication to serving patients and utilizing breakthrough advancements, Presbia PLC continues to establish itself as a leader in the ophthalmic industry.

Presbia PLC is primarily present in Europe, including countries like Germany, France, Spain, Italy, and the United Kingdom. They also have a significant presence in Middle Eastern countries such as Saudi Arabia, United Arab Emirates, and Kuwait. Additionally, Presbia PLC operates in the Asia Pacific region, specifically in countries like Japan, South Korea, Australia, and Singapore. With their global reach, Presbia PLC aims to provide their innovative solutions for presbyopia treatment to a vast customer base in various countries and regions.

Presbia PLC has achieved several significant milestones over the years. In 2016, the company received approval from the U.S. Food and Drug Administration (FDA) for its Flexivue Microlens™, making it the first and only microlens approved for the treatment of presbyopia. This approval opened up new opportunities for Presbia in the global refractive vision correction market. In 2018, the company reached a major milestone by treating its 3,000th patient with the Flexivue Microlens™. This achievement highlights Presbia's dedication to providing a safe and effective solution for age-related vision loss. With its innovative product, Presbia PLC continues to make strides in the field of presbyopia correction.

Presbia PLC is a renowned medical device company specializing in the treatment of presbyopia. Established in 2008, Presbia PLC has been at the forefront of developing innovative solutions for this common vision condition. The company's main product is the Presbia Flexivue Microlens™, a tiny lens insert that improves near vision and reduces the need for reading glasses. Presbia PLC boasts a team of experienced professionals dedicated to improving quality of life for presbyopia sufferers around the globe. With a strong emphasis on research and development, Presbia PLC continues to lead the market with safe and effective vision correction solutions.

Presbia PLC faces competition in the market from companies such as AcuFocus Inc., ReVision Optics Inc., and Kamra Vision.

Presbia PLC is primarily active in the medical devices industry, specifically focusing on the development and commercialization of optical lens implants for the treatment of presbyopia, a common condition affecting near vision as people age. With its innovative Flexivue Microlens™ technology, Presbia aims to provide a convenient and long-term solution for individuals seeking to reduce dependence on reading glasses. Presbia's expertise lies in ophthalmology and ocular procedures, making it a key player in the medical devices sector, revolutionizing the way presbyopia is treated and improving the quality of life for patients worldwide.

The business model of Presbia PLC revolves around presbyopia-correcting optical lens technology. Presbia specializes in the development and commercialization of micro-optical lenses that are implanted into the cornea to treat presbyopia, a common age-related condition that affects near vision. By offering a minimally invasive alternative to traditional methods, Presbia aims to provide patients with improved vision and reduced dependence on reading glasses or contact lenses. Through its innovative lens technology and strategic partnerships, Presbia strives to meet the growing demand for effective solutions in presbyopia treatment, benefiting individuals worldwide.

Pašreizējais KGV Presbia nevar tikt aprēķināts.

KUV šobrīd Presbia nevar aprēķināt.

AlleAktien kvalitātes vērtējums Presbia ir 2/10.

Pašreiz nevar aprēķināt apgrozījumu Presbia.

Pašlaik peļņa Presbia nevar tikt aprēķināta.

Presbia PLC is an Irish multi-product company specializing in the development of innovative medical solutions. The company focuses on developing and selling products for the correction of age-related farsightedness, known as presbyopia, as well as drug development in the field of ophthalmology. The company's patented micro-lens implant called "Flexivue Microlens" is at the center of its focus. This implant is a tiny and foldable lens that is inserted into the eye to improve vision. The micro-lens implant was developed to ensure a safe and minimally invasive eye surgery and has already received CE marking (European approval process). Presbia PLC has already successfully implanted over 5,000 implants worldwide. The implant has a high customer satisfaction rate and improves vision for age-related farsightedness in a wide range of patients with different dioptic values. In addition to the micro-lens implant, Presbia PLC is also working on the development of drugs for the treatment of eye diseases. The company has already successfully conducted phase I and II clinical trials for the development of drugs for the treatment of eye diseases such as dry eye and optic neuritis. Presbia PLC distributes its products and solutions worldwide and has offices in Europe, Asia, and the US. The company uses a model based on strategic partnerships with ophthalmologists, clinics, and hospitals. The goal of Presbia PLC is to become the number one in the field of age-related vision correction and eye diseases while ensuring the highest quality and safety of its products. Overall, Presbia PLC is an extremely successful company that focuses on the development and marketing of highly innovative medical solutions. Through the use of strategic partnerships and a focus on the highest quality and safety of its products, the company has a strong position in the market and a great potential for future growth.

Presbia izmaksā dividendes 0 USD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Presbia vai uzņēmums nedod dividendes.

Presbia ISIN ir IE00BJ0X7W22.

Presbia simbols ir LENSF.

Pēdējo 12 mēnešu laikā Presbia maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos Presbia plāno maksāt dividendes 0 USD apmērā.

Presbia pašreizējā dividendu rentabilitāte ir .

Presbia maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Presbia pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 USD. Tas atbilst dividendes ražībai 0 %.

Presbia tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Presbia apmērā 0 USD, kas tika izmaksāta 16.09.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 16.09.2024..

Pēdējās dividendes izmaksa notika 16.09.2024..

Gadā 2023, Presbia izmaksāja 0 USD dividendes.

Presbia dividendes tiek izmaksātas USD.